Sign in
WithdrawnPhase 2

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Key facts

Who runs it
Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 2
Started
1 Jun 2024
Expected to end
1 Apr 2029
Type of study
Interventional
Treatments tested
  • Aumolertinib
Record updated
10 December 2024
Why it stopped
Slow accrual

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Target population is high risk NSCLC with resection option for potential cure, as assessed by a faculty surgeon at SYSUCC. This may include clinical stage IB (≥4cm), II and IIIA. Subjects with N3 nodal involvement are not included
  • Subjects should have a detected sensitizing EGFR
  • Written informed consent provided
  • Male and female, aged 18-75 years
  • Able to comply with the required protocol and follow-up procedures, and able to receive oral medications
  • Blood and specimens before and after treatment must be provided
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Life expectancy ≥12 weeks
  • EGFR activating mutation in exon 19 or 21
  • Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level)
  • Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases
  • Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min
  • Female subjects should not be pregnant or breast-feeding

Who cannot take part

  • Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab)
  • A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study
  • Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease)
  • Known severe hypersensitivity to aumolertinib or any of the excipients of this product
  • Evidence of clinically active interstitial lung disease
  • Eye inflammation not fully controlled or conditions predisposing the subject to this
  • A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease
  • History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted
  • Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)
  • Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
  • Ingredients mixed with small cell lung cancer patients
  • History of neurologic or psychiatric disorders
  • Inability to comply with protocol or study procedures
  • Women who are pregnant or nursing

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.

The group in the trial

  • AumolertinibTreatment being tested

    Aumolertinib 110 mg once daily (110 mg per day) orally for 36 months.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single-Arm, Open-Lable Study of Adjuvant Aumolertinib for Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Record updated
10 December 2024